All In Biotech

NDA 021730 · Lupin

Xopenex Hfa

Levalbuterol Tartrate · Inhalation

Last checked: Nov 20, 2026Latest source record: Feb 27, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Mar 11, 2005

Approved uses

2

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

3,733

1,628 serious, 129 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2025.

XOPENEX HFA is a beta 2 -adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) 1.1 Bronchospasm XOPENEX HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

Mechanism: Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn, inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Levalbuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XOPENEX HFA · LEVALBUTEROL TARTRATE EQ 0.045MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levalbuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device delivery system issue642
  • drug dose omission by device556
  • no adverse event510
  • dyspnoea440
  • headache244
  • nausea229
  • fatigue225
  • cough213
  • asthma210
  • off label use197
  • dizziness174
  • pneumonia172

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20067
200724
200845
200933
201028
201142
201278
201378
201492
2015141
2016294
2017190
2018167
2019190
2020210
2021145
2022178
2023358
2024471
2025545
2026417

Recalls

2 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xopenex HFA (Levalbuterol Tartrate)

2024 spending

$1.5M

Beneficiaries

6,461

15,310 claims

Per beneficiary

$232

$4.57 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$141,407
2024$1,496,738

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Lupin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.